severe dry eye syndrome
Ophthalmology · 2018–2023
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| carmellose sodium with glycerol and sodium hyaluronate Treatment of severe dry eye syndrome. | May 2023 | Recommended | none received |
| perfluorohexyloctane Treatment of severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops. | Mar 2018 | Recommended with restriction | unclear |
What the PBS pays
$9M in government benefit over 2024–25, across 288,561 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| carmellose sodium with glycerol and hyaluronic acid | $4.9M |
| perfluorohexyloctane | $3.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.